Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$12.32 USD

12.32
6,405,600

-0.31 (-2.45%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kinjel Shah headshot

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed at $212.31 in the latest trading session, marking a +1.61% move from the prior day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $192.48, marking a +0.12% move from the previous day.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $192.24, marking a -1.1% move from the previous day.

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

Mark Vickery headshot

Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More

The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.

Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

Novavax (NVAX) Stock Moves -0.25%: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.

Sanghamitra Saha headshot

Novavax Vaccine to Get U.S. Approval? ETFs to Benefit

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $207.61, marking a +0.15% move from the previous day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $202.09, marking a +0.37% move from the previous day.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed at $179.74 in the latest trading session, marking a +1.97% move from the prior day.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Company News for Apr 7, 2021

Companies in The News Are: ILMN, NVAX, MRNA, BP.